Serge Picaud

Dr Serge Picaud, is the executive Director of the Paris Vision Institute (France). Trained in Neurosciences and biochemistry in France, Germany and the USA, he has developed over the past thirty years successful research on the development of therapies for eye neurodegenerative diseases including retinitis pigmentosa, age-related macular degeneration, optic nerve atrophy or glaucoma. 

His recent research has focused on sight restoration for blind patients. The results of these projects have been translated in clinical applications with ongoing clinical trials. His work has generated over 150 peer-reviewed publications in the field of Sensory Neurosciences with more than 20 patents leading to the creation of several spinoff companies including Fovea Pharmaceuticals, Pixium Vision, Gensight biologics, Gamut Therapeutics, PropheSee, Iconeus. 

He has also shown leadership as a founder and current Executive Director of the Paris Vision Institute, which is now integrated in the Institut Hospitalo-Universitaire FOReSIGHT together with the National Hospital Center for Ophthalmology (CHNO), to speed up the transfer of therapies toward clinical trials and patients.